Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

Journal of Cellular Biochemistry

Volumn 92, Issue 2, 2004, Pages 223-237

  Marchion, Douglas C ^a   Bicaku, Elona ^a   Daud, Adil I ^a   Richon, Victoria ^b   Sullivan, Daniel M ^a   Munster, Pamela N ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Aton Pharma Inc   (United States)

Author keywords

Breast cancer; Epirubicin; Histone deacetylase inhibitors; Suberoylanilide hydroxamic acid; Synergy; Topoisomerase inhibitors

Indexed keywords

GYRASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; VORINOSTAT; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME INHIBITOR; EPIRUBICIN; HISTONE; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; CHROMATIN CONDENSATION; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DNA DRUG COMPLEX; DRUG ACETYLATION; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; ACETYLATION; CELL CYCLE; CELL NUCLEUS; CHEMISTRY; CHROMATIN ASSEMBLY AND DISASSEMBLY; ELECTRON MICROSCOPY; METABOLISM; TUMOR CELL LINE;

ACETYLATION; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DRUG SYNERGISM; ENZYME INHIBITORS; EPIRUBICIN; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; MICROSCOPY, ELECTRON;

EID: 16544379283     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20045     Document Type: Article

References (27)

1. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM. 2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99:11700-11705.
2. Capranico G, Riva A, Tinelli S, Dasdia T, Zunino F. 1987. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei. Cancer Res 47:3752-3756.
3. Capranico G, De Isabella P, Penco S, Tinelli S, Zunino F. 1989. Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells. Cancer Res 49:2022-2027.
4. Carrier F, Georgel PT, Pourquier P, Blake M, Kontny HU, Antinore MJ, Gariboldi M, Myers TG, Weinstein JN, Pommier Y, Fornace AJ, Jr. 1999. Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol Cell Biol 19:1673-1685.
5. Chou TC, Motzer RJ, Tong Y, Bosl GJ. 1994. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524.
6. Grunstein M. 1997. Histone acetylation in chromatin structure and transcription. Nature 389:349-352.
7. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH. 1995. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55: 1707-1716.
8. Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. 2001. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98:1897-1903.
9. Huang L, Pardee AB. 2000. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6:849-866.
10. Huang L, Sowa Y, Sakai T, Pardee AB. 2000. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19: 5712-5719.
11. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. 1999. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-150.
12. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J. 2000. Amplification and deletion of topoisomerase IIalpha associate with ErbB- 2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847.
13. Johnson CA, Padget K, Austin CA, Turner BM. 2001. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J Biol Chem 276:4539-4542.
14. Kurz EU, Sara E, Wilson X, Kelly B, Leader X, Brante P, Sampey X, William P, Allan X, Jack C, Yalowich X, David J, Kroll X. 2002. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 1:121-131.
15. Marks PA, Rifkind RA, Richon VM, Breslow R. 2001. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res 7:759-760.
16. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandai M, Vadlamudi RK, Kumar R. 2001. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3:30-37.
17. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. 2001. The histone deacetylase inhibitor suberoylanilide hydroxamic Acid induces differentiation of human breast cancer cells. Cancer Res 61:8492-8497.
18. Nusse M, Beisker W, Hoffmann C, Tarnok A. 1990. Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements. Cytometry 11:813-821.
19. Osheroff N. 1989. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther 41:223-2241.
20. Ross WE, Bradley MO. 1981. DNA double-stranded breaks in mammalian cells after exposure to intercalating agents. Biochim Biophys Acta 654:129-134.
21. Sullivan DM, Eskildsen LA, Groom KR, Webb CD, Latham MD, Martin AW, Wellhausen SR, Kroeger PE, Rowe TC. 1993. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Mol Pharmacol 43:207-216.
22. Sullivan DM, Latham MD, Rowe TC, Ross WE. 1989. Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry 28:5680-5687.
23. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, Seto E. 2000. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 26:349-353.
24. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC. 2001. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7:971-976.
25. Zhou Q, Chowbay B. 2002. Determination of doxorubicin and its metabolites in rat serum and bile by LC: Application to preclinical pharmacokinetic studies. J Pharm Biomed Anal 30:1063-1074.
26. Zhou Z, Zwelling LA, Ganapathi R, Kleinerman ES. 2001. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta. Br J Cancer 85: 747-751.
27. Zwelling LA, Kerrigan D, Michaels S. 1982. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: Comparison with adriamycin and 4′-(9-acridinylamino)methanesulfon-m-anisidide. Cancer Res 42:2687-2691.